Nature of the Event

Viyash Scientific Limited has announced the acquisition of Italy's BioForLife Italia S.r.l. through its wholly owned subsidiary Alivira Animal Health Limited. This constitutes a strategic expansion into the European companion animal health market.

Key Quantitative Figures

  • Acquisition price: Approximately ₹188 crore in cash consideration
  • Stake acquired: 100% of BioForLife Italia S.r.l.
  • Market reach: BioForLife reaches over 80% of all veterinary clinics in Italy
  • Employee base: Viyash Scientific has over 3,000 employees globally

Parties Involved

  • Acquiring entity: Viyash Scientific Limited (formerly Sequent Scientific Limited)
  • Acquiring subsidiary: Alivira Animal Health Limited (wholly owned subsidiary)
  • Target company: BioForLife Italia S.r.l. (BFL)
  • Location: Milan, Italy
  • Regulatory filing: Made to BSE Limited and National Stock Exchange of India Limited
  • Contact persons: Yoshita Vora (Company Secretary), Abhishek Singhal (Investor Relations Consultants)

Purpose and Rationale

The acquisition represents a strategic step in Viyash's strategy to capitalize on the growing Companion Animal Health Generics market. It expands Alivira's global Companion Animal Health business and strengthens its presence in the European pet care market. Italy is among the five largest animal health markets in Europe, with companion animal care emerging as its fastest-growing segment.

Operational and Strategic Impact

BioForLife specializes in development, commercialization and distribution of pet care products with a strong portfolio in:

  • Nutritional complements
  • Pharmaceuticals
  • Rapid diagnostic tests
  • Emerging segments: dermatology and ophthalmology

The acquisition provides a platform for launching new products from Alivira's pipeline in Italy while simultaneously providing opportunities to expand the BFL range to other markets in the Alivira group located in Europe, Middle East, Asia and Latam.

Management Commentary

Dr. Haribabu Bodeputi, Managing Director and Group CEO, stated: "This acquisition represents another important step in our strategy to build a leading global Companion Animal Health business. BioForLife provides us with an established platform in Italy, one of Europe's most attractive pet care markets, while strengthening our presence across the region."

Integration and Team Structure

The transaction strengthens the Alivira team with the induction of BFL executives who will continue to run the business operations in addition to driving new growth initiatives.

Company Background

Viyash Scientific Limited (formerly Sequent Scientific Limited) is headquartered in Hyderabad, India and is globally among the leading Animal Health companies. The company has:

  • Manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA
  • Approvals from international regulatory bodies including USFDA, EUGMP, WHO, TGA
  • Serves customers in 100+ countries